ESR1 and bladder transitional cell carcinoma: However, selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifen have been consistently reported to inhibit the proliferation and invasion of urinary bladder urothelial carcinoma [19, 20, 30–32].